...
首页> 外文期刊>Molecular cancer therapeutics >Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
【24h】

Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box

机译:通过筛选开放式疟疾盒鉴定靶向转移性骨肉瘤的新型Ezrin抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Ezrin is a member of the ERM (ezrin, radixin, moesin) family of proteins and functions as a linker between the plasma membrane and the actin cytoskeleton. Ezrin is a key driver of tumor progression and metastatic spread of osteosarcoma. We discovered a quinoline-based small molecule, NSC305787, that directly binds to ezrin and inhibits its functions in promoting invasive phenotype. NSC305787 possesses a very close structural similarity to commonly used quinoline-containing antimalarial drugs. On the basis of this similarity and of recent findings that ezrin has a likely role in the pathogenesis of malaria infection, we screened antimalarial compounds in an attempt to identify novel ezrin inhibitors with better efficacy and drug properties. Screening of Medicines for Malaria Venture (MMV) Malaria Box compounds for their ability to bind to recombinant ezrin protein yielded 12 primary hits with high selective binding activity. The specificity of the hits on ezrin function was confirmed by inhibition of the ezrin-mediated cell motility of osteosarcoma cells. Compounds were further tested for phenocopying the morphologic defects associated with ezrin suppression in zebrafish embryos as well as for inhibiting the lung metastasis of high ezrin-expressing osteosarcoma cells. The compound MMV667492 exhibited potent anti-ezrin activity in all biologic assays and had better physicochemical properties for drug-likeness than NSC305787. The drug-like compounds MMV020549 and MMV666069 also showed promising activities in functional assays. Thus, our study suggests further evaluation of antimalarial compounds as a novel class of antimetastatic agents for the treatment of metastatic osteosarcoma. (C) 2015 AACR.
机译:None

著录项

  • 来源
    《Molecular cancer therapeutics》 |2015年第11期|共11页
  • 作者单位

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Johns Hopkins Univ Bloomberg Sch Publ Hlth Dept Biochem &

    Mol Biol Baltimore MD USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    George Mason Univ Dept Chem &

    Biochem Manassas VA USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

    Johns Hopkins Univ Bloomberg Sch Publ Hlth Johns Hopkins Malaria Res Inst Baltimore MD USA;

    Georgetown Univ Med Ctr Dept Oncol Washington DC 20057 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号